Background
Endometrial stromal tumors are uncommon; they account for less than 10% of uterine mesenchymal neoplasms and less than 2% of all uterine tumors [
1]. They are sorted by the 2014 World Health Organization (WHO) classification into four categories: endometrial stromal nodule, low-grade endometrial stromal sarcoma (ESS), high-grade ESS, and undifferentiated uterine sarcoma [
2]. Low-grade ESS is the second most common mesenchymal malignancy of the uterus and recently characterized by harboring the genetic rearrangement t (7;17)(p15;q21) resulting in
JAZF1–SUZ12 gene fusion [
3]. Low-grade ESS is typically slow growing, in which high uptake of fluorodeoxyglucose (FDG) on positron emission tomography (PET) and subserosal masses are much less common than in leiomyosarcomas. Here, we describe a woman with
JAZF1–SUZ12 ESS of the uterine corpus forming two sizeable subserosal masses other than a conventional intramural component, the two former of which exhibited exceptionally high FDG uptake on PET/computed tomography indicating distinctive heterogeneity in proliferative activity within a single tumor.
Discussion
The t (7;17) translocation resulting in fusion of the
JAZF1 gene (on chromosome 7p15) to the
SUZ12 gene (on 17q21) represents the most common chromosomal rearrangement in low-grade endometrial stromal tumors, being detected in approximately 30% of low-grade ESS and 50% of endometrial stromal nodules tested [
4,
5]. Those tumors share characteristic morphologic features of spindle-cell proliferation similar to those of proliferative-phase endometrial stroma, typically lacking significant cytologic atypia and mitotic activity (usually < 5 counts per 10 HPF) [
2]. The current WHO Classification of Tumors of Female Genital Organs 2014 reintroduced a terminology of high-grade ESS, which was formerly classified into undifferentiated stromal sarcoma and recently reported to harbor the specific
YWHAE rearrangement in most cases [
6]. High-grade ESS consistently shows uniform cytomorphology, about half of which are biphasic where a round-cell component with mitotic activity (typically > 10 per 10 HPF) is admixed with a low-grade-ESS like spindle-cell component commonly with fibrous/fibromyxoid stroma [
7]. Immunohistochemically, the round-cell component usually shows > 70% cyclin D1 nuclear staining of the tumor cells with homogenous moderate to strong intensity, in contrast to the form of scattered positive cells (< 5%) in classic
JAZF1 rearranged endometrial stromal tumors [
8]. In the present case, the clinically rapid growing component with high FDG uptake demonstrated around 50% cyclin D1 nuclear immunostaining of neoplastic cells with up to moderate intensity, which indicates the low-grade-ESS like component possibly comprising
YWHAE rearranged ESS as Lee et al. reported [
8]. This paradoxical heterogeneity in a single
JAZF1–SUZ12 ESS with a zonal uptake of FDG has never been documented.
Subserosal masses are much less common in endometrial stromal tumors than in smooth-muscle tumors. The uterine corpus is the most common location for endometrial stromal tumors, although extrauterine locations, specifically the peritoneal surfaces, can be primary sites for the tumor in association with endometriosis, including the ovary, pelvis, fallopian tubes, abdominal cavity, vulva, vagina, bowel wall, urinary bladder, retroperitoneum, and lymph nodes [
9,
10]. Recently, Agaimy et al. reported a man with
JAZF1–SUZ12 ESS arising in the paratestis as an extremely rare case [
11]. Typically, macroscopic ESS growth patterns feature any combination of (1) intramyometrial nodular masses, (2) an intracavitary polypoid mass, or (3) diffuse myometrial infiltration within expanded uterine walls [
2]. The gross appearance of endometrial stromal tumors is occasionally mixed with hemorrhages and necrosis, which may complicate differentiating them from leiomyosarcomas especially when uterine subserosal tumors demonstrate strikingly high FDG uptake. Overt myometrial infiltrations and/or intravascular, worm-like (or “tongue-like”) plugs of tumor protruding from intramyometrial or parametrial veins, which are occasionally recognizable on gross examination, are important in distinguishing ESS from leiomyosarcomas [
9]. We speculate the two subserosal masses are metastatic from the intramural lesion based on the identical molecular findings and the presence of venous extrauterine permeation.
There were few reports on FDG-PET findings of ESS histologically examined in a large case series; Yamamoto et al. assessed the mean SUV of
18F-FDG-PET of 12 uterine sarcomas (8 leiomyosarcomas, 2 high-grade ESS, and 2 low-grade ESS) at 6.1 ± 3.7 (range, 1.7–13.5; the highest SUV of ESS was 11.70) [
12]. Zhao et al. reported the mean SUV of
18F-FDG-PET of the largest series of 14 uterine malignancies with a mesenchymal component (8 leiomyosarcomas, 3 carcinosarcomas, 1 ESS, and 2 undifferentiated endometrial sarcomas) to be 5.5 ± 3.1 (range, 1.8–12.0) [
13]. To the best of our knowledge in the literature, SUV of 13.28 in the present case is the highest
18F-FDG uptake in uterine ESS even though there was no radiologic reason for the exceptional uptake, e.g. coexisting histologic inflammation in tumors. In the present case, preoperative levels of serum CA 125 and LDH were slightly elevated, and the former was normalized postoperatively in contrast to the latter staying at a level around 300 U/L. Therefore, CA 125 may be useful for the diagnosis of uterine sarcomas, although this remains nonspecific due to the possibility of stimulated mesothelial cells.
Low-grade ESS is usually indolent with five-year disease specific survival for stages I and II being 90% compared to 50% for stages III and IV [
14]. Patients with high-grade ESS have earlier and more frequent recurrences (often < 1 year) and are more likely to die of disease [
7], likely to have an intermediate prognosis between low-grade ESS and undifferentiated uterine sarcoma, the latter of which is usually aggressive and exhibits remarkable pleomorphism with no specific translocation pattern [
15,
16]. Since the prognosis of patients with
JAZF1–SUZ12 ESS harboring focally high proliferative activity is still unclear, careful follow-up is recommended and future investigations should target this heterogeneity in a single ESS to clarify its prognostic value.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.